I. Varthalitis

发表

XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis

K. Syrigos, T. Economopoulos, G. Fountzilas, 2012, BMC Cancer.

Impact of tumor angiogenic profile on the outcome of patients with metastatic breast carcinoma treated with weekly docetaxel. A Hellenic Cooperative Oncology Group (HeCOG) study.

G. Aravantinos, G. Fountzilas, P. Kosmidis, 2015, Histology and histopathology.

Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study.

S. Agelaki, V. Georgoulias, K. Syrigos, 2011, Clinical lung cancer.

Management of Cancer-associated Thrombosis (CAT): Symptomatic or Incidental

I. Boukovinas, G. Aravantinos, C. Papandreou, 2020, AntiCancer Research.

Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group

I. Boukovinas, N. Ziras, V. Georgoulias, 2017, British Journal of Cancer.

Lessons from the past: Long-term safety and survival outcomes of a prematurely terminated randomized controlled trial on prophylactic vs. hemoglobin-based administration of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia.

G. Aravantinos, G. Fountzilas, G. Mountzios, 2016, Molecular and clinical oncology.

Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients

I. Boukovinas, G. Aravantinos, G. Pentheroudakis, 2019, PloS one.

Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab

F. Fostira, A. Antonacopoulou, H. Kalofonos, 2011, The Pharmacogenomics Journal.

Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.

U. Dafni, H. Gogas, C. Markopoulos, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

A multicenter phase I trial of metronomic oral vinorelbine plus cisplatin in patients with NSCLC

V. Georgoulias, I. Varthalitis, A. Pallis, 2011, Cancer Chemotherapy and Pharmacology.

Modified CAPOX (Capecitabine plus Oxaliplatin) Regimen Every Two Weeks as Second-Line Treatment in Patients with Advanced Colorectal Cancer Previously Treated with Irinotecan-Based Frontline Therapy

N. Ziras, J. Souglakos, A. Polyzos, 2008, Oncology.

Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group study

M. Dimopoulos, N. Pavlidis, G. Fountzilas, 2008, Cancer Chemotherapy and Pharmacology.

Expression of angiogenic markers in the peripheral blood of docetaxel-treated advanced breast cancer patients: a Hellenic Cooperative Oncology Group (HeCOG) study.

G. Aravantinos, H. Kalofonos, G. Fountzilas, 2011, Oncology reports.

Utilization of Systemic Chemotherapy in Advanced Urothelial Cancer: A Retrospective Collaborative Study by the Hellenic Genitourinary Cancer Group (HGUCG).

M. Dimopoulos, A. Papatsoris, M. Karamouzis, 2016, Clinical genitourinary cancer.

Systemic Chemotherapy in Urothelial Cancer Introduction

M. Dimopoulos, A. Papatsoris, M. Karamouzis, 2022 .

Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study

G. Fountzilas, G. Pentheroudakis, C. Dervenis, 2018, Targeted Oncology.

First line combination chemotherapy with cisplatin and etoposide in advanced ovarian cancer.

D. Pectasides, I. Varthalitis, D. Bafaloukos, 1989, British Journal of Cancer.

The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer--further observations from the IMPACT solid study.

K. Krzemieniecki, F. Erdkamp, H. Lindman, 2016, Breast.

Real-World Data on Thromboprophylaxis in Active Cancer Patients: Where Are We? Are We Getting There?

I. Boukovinas, G. Aravantinos, C. Papandreou, 2020, Cancers.

A multicenter randomized study comparing vinorelbine plus gemcitabine versus capecitabine monotherapy as salvage treatment in patients with advanced breast cancer pretreated with taxane and anthracycline chemotherapy: A preliminary report.

K. Syrigos, V. Georgoulias, I. Boukovinas, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pneumocystis carinii pneumonia in cancer patients.

F. Meunier, I. Varthalitis, 1993, Cancer treatment reviews.

Pneumocystis carinii pneumonia in patients with cancer. An increasing incidence

F. Meunier, M. Aoun, I. Varthalitis, 1993, Cancer.

Pneumocystis carinii pneumonia: the pathogen, the diagnosis and recent advances in management.

F. Meunier, I. Varthalitis, 1991, International journal of antimicrobial agents.

Prophylaxis of Fungal-infections

F. Meunier, I. Varthalitis, 1995 .

Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer

A. Psyrri, G. Fountzilas, G. Pentheroudakis, 2019, ESMO Open.

Treatment of Primary Fallopian Tube Carcinoma with Cisplatin‐Containing Chemotherapy

D. Pectasides, I. Varthalitis, V. Barbounis, 1994, American journal of clinical oncology.

Multicenter Phase II Study of Gemcitabine and Oxaliplatin (GEMOX) as Second-Line Chemotherapy in Colorectal Cancer Patients Pretreated with 5-Fluorouracil plus Irinotecan

K. Syrigos, I. Boukovinas, N. Ziras, 2006, Oncology.

Α multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer

V. Georgoulias, G. Samonis, N. Ziras, 2011, Cancer Chemotherapy and Pharmacology.

A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer.

V. Georgoulias, S. Agelaki, I. Varthalitis, 2009, Lung cancer.

Observational Study of Clinical Practice in Patients with Pancreatic Adenocarcinoma in Greece

I. Boukovinas, G. Aravantinos, D. Mauri, 2020, Journal of oncology.

A prospective, randomized study of pefloxacin versus teicoplanin in the treatment of gram-positive coccal infections in cancer patients: early termination due to emergence of resistance to fluoroquinolones

F. Meunier, I. Varthalitis, P. Auwera, 1994, Supportive Care in Cancer.

Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study

H. Gogas, G. Aravantinos, K. Papadopoulou, 2015, PloS one.

Predictive biomarkers to chemotherapy in patients with advanced melanoma receiving the combination of cisplatin--vinblastine--temozolomide (PVT) as first-line treatment: a study of the Hellenic Cooperative Oncology Group (HECOG).

H. Gogas, G. Fountzilas, G. Pentheroudakis, 2015, Anticancer research.

Adjuvant Chemotherapy With Dacarbazine, Vindesine, and Cisplatin in Pathological Stage II Malignant Melanoma

D. Pectasides, I. Varthalitis, G. Asimakopoulos, 1994, American journal of clinical oncology.

Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping

K. Syrigos, E. Giannoulatou, G. Fountzilas, 2018, Medical Oncology.

Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group

V. Georgoulias, G. Fountzilas, S. Agelaki, 2017, British Journal of Cancer.

FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG)

Vassilis Georgoulias, A. Adamou, D. Mavroudis, 2009, Breast Cancer Research and Treatment.

Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative

E. Giannoulatou, H. Gogas, Jianhua Zhang, 2020, Oncotarget.

Prophylaxis of cancer-associated venous thromboembolism with low-molecular-weight heparin-tinzaparin: Real world evidence

I. Boukovinas, G. Aravantinos, C. Papandreou, 2022, Oncology letters.

A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research Group

V. Georgoulias, S. Agelaki, I. Varthalitis, 2013, Journal of chemotherapy.

Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma

F. Fostira, C. Papadimitriou, G. Aravantinos, 2021, Cancers.

Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial

M. Dimopoulos, U. Dafni, N. Pavlidis, 2014, BMC Cancer.

Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study

I. Boukovinas, G. Aravantinos, G. Fountzilas, 2013, BMC Cancer.

Front-Line Chemotherapy with Docetaxel and Gemcitabine Administered Every Two Weeks in Patients with Metastatic Breast Cancer: A Multicenter Phase II Study

V. Georgoulias, N. Malamos, D. Mavroudis, 2004, Oncology.

A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer

S. Agelaki, V. Georgoulias, K. Syrigos, 2010, BMC Cancer.

A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer.

V. Georgoulias, I. Boukovinas, N. Malamos, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG)

N. Pavlidis, G. Fountzilas, G. Pentheroudakis, 2014, BMC Cancer.

Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial.

D. Mavroudis, V. Georgoulias, I. Boukovinas, 2008, Lung cancer.

Case-Mix Adjustment Approach to Benchmarking Prevalence Rates of Nosocomial Infection in Hospitals in Cyprus and Greece

Evangelos I. Kritsotakis, A. Gikas, I. Varthalitis, 2008, Infection Control & Hospital Epidemiology.

K. Syrigos, T. Economopoulos, G. Fountzilas, 2012, BMC Cancer.

Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group

V. Georgoulias, I. Boukovinas, J. Souglakos, 2017, Annals of gastroenterology.

A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy

V. Georgoulias, D. Mavroudis, I. Varthalitis, 2016, British Journal of Cancer.

Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study

I. Boukovinas, G. Aravantinos, G. Fountzilas, 2013, BMC Cancer.

Prognostic significance of tumor genotypes and CD8+ infiltrates in stage I-III colorectal cancer

G. Aravantinos, A. Psyrri, K. Papadopoulou, 2018, Oncotarget.

A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer.

D. Mavroudis, V. Georgoulias, I. Boukovinas, 2012 .

Immune Response Gene Expression in Colorectal Cancer Carries Distinct Prognostic Implications According to Tissue, Stage and Site: A Prospective Retrospective Translational Study in the Context of a Hellenic Cooperative Oncology Group Randomised Trial

K. Syrigos, R. Wirtz, G. Lazaridis, 2015, PloS one.

Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).

J. S. Lee, D. R. Berry, G. Giaccone, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer.

G. Aravantinos, T. Economopoulos, K. Syrigos, 2010, Anticancer research.

Treatment of an unresectable cardiac angiosarcoma using paclitaxel and image guided radiotherapy: Case report and literature review.

E. Pantelis, G. Agrogiannis, I. Varthalitis, 2023, Clinical and translational radiation oncology.

3036 G-CSF use and neutropenic events in patients with breast and lung tumours: data from routine clinical practice (IMPACT Solid study)

P. Sevelda, K. Krzemieniecki, F. Erdkamp, 2009 .

A. Adamou, D. Mavroudis, V. Georgoulias, 2009, Breast Cancer Research and Treatment.

Three versus six months adjuvant oxaliplatin plus fluoropyrimidine chemotherapy for patients with stage III colon cancer: The Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant (IDEA) chemotherapy project.

V. Georgoulias, I. Boukovinas, N. Ziras, 2018 .